Emzor Pharmaceutical Industries Limited has unveiled fresh plans to combat malaria in Nigeria.
In a statement issued by the executive director, Uzoma Ezeoke, the company said with the imminent completion of its $23 million Active Pharmaceutical Ingredients (API) facility in Shagamu, Ogun State, Emzor is poised to revolutionise malaria control efforts in Nigeria and Africa.
The statement read in part: “Malaria remains a significant public health challenge in Nigeria and Sub-Saharan Africa, with Nigeria bearing the highest burden globally.
“Emzor has played a crucial role in combating the disease through extensive research and development efforts, manufacturing life-saving antimalarial drugs, and supporting public health programmes.
“Emzor’s commitment to innovation is exemplified by its state-of-the-art API plant in Shagamu. This facility will enable local production of critical pharmaceutical ingredients essential for antimalarial drugs. By strengthening the supply chain, Emzor aims to address the endemic nature of malaria and reduce its devastating impact on public health.
“The API plant not only addresses immediate health needs but also promotes financial inclusion and gender equality. Through the production of APIs for antimalarial drugs, Emzor empowers health workers, particularly women, and contributes to achieving Sustainable Development Goal 3: Good Health and Well-being.
“Emzor Pharmaceutical Industries Limited is leading the charge against malaria, showcasing the transformative power of innovation and commitment to public health.
“With the completion of its API plant, the company reaffirms its dedication to strengthening Africa’s pharmaceutical sector and bringing hope to millions affected by malaria.
“As global efforts intensify, Emzor’s contributions mark a significant step towards eradicating malaria once and for all.”
